SOFIVA GENOMICS

Stock Code 6615

Investor Conference

2025 / 06 / 25

Chairman
Yi-Ning Su, MD. Ph.D

Disclaimer

All statements for investors contain information that represent, other than historical facts, SOFIVA's plans and forward-looking statements are based upon management's current assumptions.

Environmental changes and other important factors could cause actual results to differ materially from those expressed in our statements.

Investors should carefully consider the investment objectives and risks before investing.

SOFIVA
GENOMICS

SOFIVA - The Dual Operating Strategy

Maternal Fetal Medicine | **Precision Cancer Medicine**

Genetic Screening Category	Servicing Specialty	Target
Reproductive	IVF Center	IVF Embryo Screening
Prenatal	OB-GYN	Pre-pregnant couples Pregnant couples
Newborn	Pediatrics, Neonatology	Child Newborn
Cancer	Cancer-related Specialty	All Target Audience (Pre-Cancer & Patient)
Rare Disease	Genetics-related Specialty	All Target Audience
Precision Medicine	Treatment-related Specialty	All Target Audience

SOFIVA GENOMICS

Maternal Fatal Medicine and Precision Cancer Medicine One Stop Service

Reproductive

- PGT-M
- PGT-A
- niPGT-A

Rare Diseases

- Hearing Loss Genetic Test v1.0/v2.0/v3.0
- Achondroplasia
- Osteogenesis Imperfecta
- Duchenne Muscular Dystrophy
- Wilson's Disease
- Marfan Syndrome
- Whole Exon Sequencing Genetic Testing

Prenatal

- NIPS
- Array
- Karyotyping
- Carrier Scan
- SMA Genetic Testing-SMN gene
- Fragile X Genetic Testing-FMR1 gene
- Thalassemia Genetic Testing-HBA,HBB gene
- Folate Metabolism Genetic Testing-MTHFR gene

Cancer

- Cancer Monitor
- Cancer Scan
- Cancer Risk v1.0/v2.0
- HPV Screening

Newborn

- Baby Scan
- Hearing Loss Genetic Screening
- CCHS Genetic Screening
- Congenital CMV Infection Screening
- Atopic Dermatitis Genetic Screening -FLG gene

Precision Medicine

- HRD Status
- CGP Genetic Test
- BRCA1/2 Genetic Testing
- Endometrial Cancer Genetic Subtypes
- Prostate Cancer Genetic Testing

SOFIVA GENOMICS

National Health Insurance (NHI)

Eligible for reimbursement under NGS testing criteria

SOFIVA
GENOMICS

Cancer Products Compliant with NGS Health Insurance Coverage

NGS Genetic Testing

Laboratory and Testing Compliant with NGS Health Insurance Coverage

Over Ten Types of Tests

14 Types Solid Tumors

5 Types Hematologic Cancers

Compliant with Health Insurance Coverage Criteria for Various Cancer Types

BRCA1/2 Genetic Testing	Coverage of $10,000 TWD
Small Panel ≤100 genes	Coverage of $20,000 TWD
Large Panel > 100 genes	Coverage of $30,000 TWD

Cancer

SOFIVA – Testing meets NGS reimbursement criteria

Over 10 types of Test

Reimbursable under NHI for various cancer types

Testing Service	No of Genes	Lung cancer	Triple-Negative Breast Cancer and Pancreatic Cancer	Ovarian, fallopian tube, and primary peritoneal cancers	Prostate Cancer	NTRK-associated Carcinoma	Biliary Tract Carcinoma	(Medullary) Thyroid Cancer
CM-Lung	26	☆☆						☆☆
CM-Breast	26							☆☆
CM v1.0	31	☆☆						☆☆
CM v2.1	77	☆☆						☆☆
CM v2.2	197							☆☆☆
CM v3.0	249	☆☆☆		☆	☆			☆☆☆
CGP	324	☆☆☆		☆	☆	☆☆☆	☆☆☆	☆☆☆
BRCA1/2	2		☆	☆	☆			
HRD	28			☆	☆			
Prostate Test	30		☆	☆	☆			
CR	44~151		☆	☆	☆			

★ 10,000 points
★★ 20,000 points
★★★ 30,000 points

Cancer

NGS reimbursement – Nationwide statistics

Statistics from NHI, as of the end of February 2025



SOFIVA GENOMICS 慧智基因

The following tests have been approved.

Category	Testing Service	No of Genes
BRCA1/2	Cancer Monitor-BRCA1/2 Cancer Risk-BRCA1/2 Cancer Risk-Woman Cancer Cancer Risk v1.0 Cancer Risk v1.0	2 2 44 67 151
Small Panel	Cancer Monitor-BRCA1/2Cancer Monitor-BRCA1/2 Cancer Monitor-BRCA1/2	26 31 77
Large Panel	CGP Cancer Genetic Testing	335

SOFIVA expands into the reimbursed testing market, driving positive revenue growth

National Health Insurance (NHI)

Eligible for drug reimbursement

Cancer

New NHI Reimbursement
PARP Inhibitor Expanded Indication

Announced by NHI (Since 1st June, 2025)

Estimated 775 patients/year

		Original NHI criteria	Estimated annual number of beneficiaries[1]
Ovarian Cancer	Takeda / AstraZeneca	BRCA1/2 mutation	**526**
Breast Cancer	AstraZeneca	Advanced or metastatic BRCA1/2 mutation	**152**
Prostate Cancer	Janssen / AstraZeneca	Received hormone therapy in prior line + BRCA mutation	**97**

➡ Expanded reimbursement criteria:
Increased number of beneficiaries, increased demand for genetic testing.

The Central News Agency (CNA) https://www.cna.com.tw/news/ahel/202505190113.aspx

Cancer

New NHI Reimbursement – Ovarian Cancer

Impact on ovarian cancer treatment in Taiwan

Statistics from SOFIVA (N = 1007) from 2022 to 2024



For ovarian cancer, BRCA testing is not enough — HRD(+) is also capable for NHI Reimbursement

- **HRD-related tests in SOFIVA: HRD, CGP**
- **Already cooperated with over 30 major medical facilities**

Compared to BRCA-only testing, HRD identified 30% more patients eligible for treatment

SOFIVA GENOMICS

Strategic Expansion into the Health Check-up Market

Cancer Scan

Health Checkup Market : Product Expansion

Preconception

Available for All Specialties: Access to Preconception Screening with Seamless Referral After Screening

Female

In Line with Regular Health Insurance Screenings, Early Screening for Women's Cancers is Crucial

Male

In Line with Regular Health Insurance Screenings, Early Screening for Men's Cancers is Crucial

Elderly

Health Management for the Elderly Population: Focus on Cancer, Aging, and Dementia

Comprehensive and Precise Health

Carrier Scan | Cancer Scan | Cancer Risk | APOE Genetic Testing

SOFIVA GENOMICS

Cancer: The Leading Cause of Death

Top 10 Cancer Causes of Death

In 2021, 120,000 New Cancer Cases (Published in 2023)
In 2023, 50,000 Cancer Deaths (Published in 2024)

Lung Cancer | Liver Cancer | Colorectal Cancer | Breast Cancer | Prostate Cancer

Early Cancer Screening Reduces Mortality Risk by up to 70%
MOHW to Increase Early Cancer Screening Budget in 2025 (from 2.8 Billion to 6.8 Billion)

Oral Cancer | Pancreatic Cancer | Stomach Cancer | Esophageal Cancer | Ovarian Cancer





SOFIVA GENOMICS

Source: MOHW, Department of Statistics

Strengthen the National Cancer Prevention and Control Program

早期癌篩、新藥基金、精準醫療 目標2030年癌死降三分之一

2024-11-29 02:40 聯合報／記者周佑政、廖靜清、賴昀岫／台北報導

總統府健康台灣推動委員會第二次會議昨天登場，衛福部提出「強化癌症防治策略」報告。圖／擷取自總統府YT頻道

- Enhance Early Cancer Screening
- Provide Coverage for Cancer Genetic Testing
- Increase Cancer New Drug Fund by Billions

Reduce Cancer Mortality Rate by One-Third by 2030

Health Check-up Market Size

衛生福利部國民健康署
Health Promotion Administration, Ministry of Health and Welfare

Utilization Rate of Preventive Health Services Among Taiwanese Adults





40-64yrs	Ages 40-64: Eligible for Screening Every 3 Years
Qualified Individuals Tested	3,035,023
Utilized Population	843,280
Service Utilization Rate	27.8%

>65yrs	Ages 65 and Above: Eligible for One Screening per Year
Qualified Individuals Tested	4,085,793
Utilized Population	1,054,877
Service Utilization Rate	25.8%

Source : Executive Yuan Gender Equality Committee; National Health Insurance Administration, 2022 Adult Preventive Health Services Payment Data File; Ministry of the Interior Population Statistics (Year-End Population)

SOFIVA GENOMICS

Strategic Expansion into the Health Check-up Market

Cancer Scan

Liquid Biopsy

Cancer Screening

What is Liquid Biopsy? Circulating Tumor DNA (ctDNA)

Cancer Cell



Normal Cell

Cell Death

Short DNA fragments
NGS Technology
Identify cancer gene mutations

Blood (Urine/Ascites...)





Br J Pharm(1):3-18. *Mol Diagn Ther* 2019; 23(3):311-331. *Chonnam Med J* 2016; 52(3): 151–158.

Cancer Scan Transforming Cancer Early Detection Strategy

Traditional health check-ups

SOFIVA Cancer Scan

Liquid biopsy

The cancer inside your body might not be detected by traditional health exams!

1

Traditional check-ups

SOFIVA Cancer Scan

Health check-up packages

Combine imaging and biochemical markers for comprehensive cancer evaluation

2

SOFIVA Cancer Scan ⟷ Traditional check-ups

APC Mutation — **Colonoscopy**

Simple blood-based screening
Order suitable traditional health exams

3

Traditional check-ups ⟷ SOFIVA Cancer Scan

Mammography — **Check for gene**

When traditional check-ups cannot confirm cancer, genetic screening can serve as a double-check tool

Traditional Health Check-ups + SOFIVA Cancer Scan
= Dual Protection Against Cancer

Strategic Expansion into the Health Check-up Market

Alzheimer's Disease Genetic Screening-APOE

SOFIVA GENOMICS

Alzheimer's Disease Genetic Screening-APOE

Rising Dementia Prevalence in an Aging Population

Due to medical advances and population aging, dementia prevalence is steadily increasing. In 2023, 7.99% of people aged 65+ had dementia, with higher rates in women than men (MOHW data).

Dementia Prevalence:
All older adults: 7.99%

6.35%
Male seniors

9.36%
Female seniors



Common Symptoms of Dementia: Memory Loss and Cognitive Changes

Dementia is a disease, not a normal part of aging. Alzheimer's disease is the leading cause, accounting for approximately 57% of dementia cases.



Alzheimer's: 60% of Dementia

SOFIVA GENOMICS

Alzheimer's Disease Genetic Screening-APOE

Prevent Early, Protect Memory

Alzheimer's Disease and APOE

APOE (Apolipoprotein E) is the most common genetic risk factor for late-onset Alzheimer's disease. Different APOE alleles influence the genetic risk of developing Alzheimer's. Research has also linked APOE variants to cardiovascular disease, dyslipidemia, diabetes, and metabolic syndrome.

How to Prevent Alzheimer's Disease?

Studies show that 75% of individuals with the APOE ε4/ε4 genotype develop Alzheimer's pathology by age 65. APOE genetic testing can help assess Alzheimer's risk. With a healthy lifestyle and balanced diet, early prevention is possible — protect your memory starting today!

75% of high-risk genotypes show pathology by age 65
→ Genetic testing enables early prevention.

Risk	Genotype	Prevalence	Alzheimer's risk	
Low	ε2/ε2	1%	Low Risk 82%	Average risk
	ε2/ε3	16%		
	ε3/ε3	65%		
	ε2/ε4	3%	Intermediate to high risk	2 to 3 times higher risk
	ε3/ε4	14%		
High	ε4/ε4	1%	High risk 1%	15 times higher risk

New therapeutic drugs

- Aβ antibody drugs: No longer just symptom relief, but actual improvement of cognitive decline.

New Alzheimer's drugs obtained Taiwan FDA indication in February and April

Self-pay cost of at least NT$1.5 million

LEQEMBI® (lecanemab-irmb) 100 mg/mL INJECTION FOR INTRAVENOUS USE 	For the treatment of patients with mild cognitive impairment and mild Alzheimer's disease (early Alzheimer's disease) due to Alzheimer's pathology. The above patients must match the population in which treatment was initiated in clinical trials, and are limited to **apolipoprotein E ε4 heterozygotes (ApoE ε4 heterozygous)** or **non-carriers of the apolipoprotein E ε4 allele (non-carriers).** **Note:** This indication is granted under **accelerated approval** based on preliminary clinical efficacy results (from a Phase 3 clinical trial). A confirmatory trial is required to verify the clinical benefit of this indication.
ONCE MONTHLY kisunla™ (donanemab-azbt) 	Treatment of patients with mild cognitive impairment and mild Alzheimer's disease (early Alzheimer's disease) due to Alzheimer's pathology, consistent with the population in which treatment was initiated in clinical trials, and limited to **apolipoprotein E ε4 heterozygotes (ApoE ε4 heterozygous)** or **non-carriers of the apolipoprotein E ε4 allele (non-carriers).**

Alzheimer's Disease Genetic Screening-APOE：
Risk assessment + medication safety evaluation

Reproductive Market Trends

Rising Demand for Later-age Fertility

Rising Trend of Advanced Maternal Age Pregnancies



Source: MOHW, Department of Statistics

Increasing Demand for PGT-A

1. The proportion of embryonic abnormalities increases with maternal age, leading to higher quality standards.
2. Routine chromosomal screening of embryos (PGT-A) is experiencing increased demand.



Source: MOHW, Department of Statistics

Infertile couples

15%

Assisted Reproductive Institutions Licensed by MOHW

74 → 102 institutions

Number of IVF Cycles

15,000 → 60,000

IVF Subsidy Launched on July 1, 2021

Proportion of Total Newborns 20%

PGT-A Development Trends

Technical Perspective: Future Advances in PGT-A

Key Clinical Discussion: Mosaic Embryo

Global Trends and Professional Society Consensus

Genes (Basel). 2023 Dec 21;15(1):18.
Proc Natl Acad Sci USA. 2021 Nov 16;118(46):e2109307118.
Fertil Steril. 2023 Nov;120(5):973-982.
Fertil Steril. 2024 Sep;122(3):421-434.

Operating Performance

Operational Performance

Statements of Comprehensive Income of last 3 years



	(In Thousands of New Taiwan Dollars)		
	2022	2023	2024
Revenue	495,775	466,797	453,312
Gross Profit	148,988	129,908	135,661
Gross Profit (%)	30.05%	27.83%	29.93%
Opreating Income	3,787	-15,882	-3,373
Total Non-Opreating Income	43,562	24,785	26,988
Pre-Tax Income	47,349	8,903	23,615
Net Income	43,153	11,923	19,128
EPS	2.00	0.54	0.86

SOFIVA GENOMICS

Revenue Trend：The Last 10 Quarters

(In Thousands of New Taiwan Dollars)



Revenue Trend：The Last 6 Months



SOFIVA GENOMICS

Investment Performance

(In Thousands of New Taiwan Dollars)			
DIANTHUS CO.,Ltd			
Statements of Comprehensive Income			
	2022	2023	2024
Sales Revenue	689,795	695,831	803,024
Comprehensive Income	253,022	142,929	153,057
Capital Stock	895,000	895,000	895,000
Investment from Sofiva	148,250	148,250	148,250
Shareholding Ratio of Sofiva	16.56%	16.56%	16.56%
Investment Income of Sofiva	41,902	23,671	25,348



SOFIVA GENOMICS Co., Ltd.

www.sofivagenomics.com

T +886-2-2382-6615

F +886-2-2382-6617

Add No.27, Baoqing Rd., Zhongzheng Dist., Taipei City 100